RecruitingPhase 3NCT05667454

MAD Trial: Myopia Atropine Dose

Investigator Led, Double-masked, Multicenter, Randomized Clinical Trial for the Comparison of Atropine 0.5% Versus Atropine 0.05% Eye Drops for the Prevention of Myopia Progression in Dutch Children


Sponsor

Erasmus Medical Center

Enrollment

550 participants

Start Date

Dec 19, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse. Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year observational period.


Eligibility

Min Age: 6 YearsMax Age: 11 Years

Inclusion Criteria6

  • Children aged 6 to ≤ 11 years with bilateral myopia
  • Onset of myopia ≥ 4 years of age
  • History of progression
  • SER of at least -1.00D and no greater than -6.00D in each eye measured using cycloplegic auto refraction
  • Intraocular pressure < 21 mm Hg in each eye
  • Distance vision correctable to at least 0.1 Log MAR (logarithm of the minimum angle of resolution) in each eye

Exclusion Criteria10

  • Allergy to atropine or other excipients of the eye drops
  • History of amblyopia or strabismus
  • History of retinal dystrophy or systemic disorder
  • Abnormal ocular biometry aside from axial length
  • History of glaucoma
  • Chronic use of topical or systemic antimuscarinic/anticholinergic medications in the 21 days prior to screening, and/or anticipated need for chronic use over the duration of the study (i.e., more than 7 consecutive days in 1 month or more than a total of 30 days in 1 year).
  • Chronic use (more than 3 days a week) of topical ophthalmological medication (prescribed or over the counter) other than the assigned study medication. The use of artificial tears is allowed but not in the 1 hour before or after the administration of the study medication.
  • The anticipated need to use chronic ophthalmic or systemic oral corticosteroids during the study. (i.e., < 2 weeks)
  • Prior myopia treatments.
  • Employees of the study center and their family members.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAtropine Ophthalmic 0.05%

Atropine 0.05% sulphate ophthalmic solution

DRUGAtropine Ophthalmic 0.5%

Atropine 0.5% sulphate ophthalmic solution


Locations(20)

Flevoziekenhuis

Almere Stad, Netherlands

OLVG, locatie Oost

Amsterdam, Netherlands

Ophthalmologistenpraktijk Delfland

Delft, Netherlands

Reinier de Graaf Gasthuis

Delft, Netherlands

Deventer Ziekenhuis

Deventer, Netherlands

Albert Schweitzer ziekenhuis

Dordrecht, Netherlands

Bergman Clinics - Ede

Ede, Netherlands

Admiraal de Ruyter Ziekenhuis

Goes, Netherlands

Frisius MC

Heerenveen, Netherlands

Oogcentrum Noordholland

Heerhugowaard, Netherlands

Leiden University Medical Center

Leiden, Netherlands

Bergman Clinics - Lelystad

Lelystad, Netherlands

Maastricht UMC+

Maastricht, Netherlands

St. Antonius

Nieuwegein, Netherlands

Radboudumc

Nijmegen, Netherlands

Erasmus Medical Center

Rotterdam, Netherlands

Haga Ziekenhuis

The Hague, Netherlands

Oogkliniek Den Haag

The Hague, Netherlands

Ziekenhuis Rivierenland Tiel

Tiel, Netherlands

Elisabeth-TweeSteden Ziekenhuis

Tilburg, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05667454